Bailard’s Sana Biotechnology SANA Stock Holding History

Bailard’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,000	Closed	-$223K	–	778
2022 Q1	$223K	Buy	+27,000	New	+$218K	0.01%	639

Other funds holding SANA

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bailard's SANA Position: Q2 2022 in Review

Bailard sold out of Sana Biotechnology (SANA) in Q2 2022, closing a stake of 27,000 shares — an estimated $223K sold.

Bailard first reported a position in SANA in Q1 2022 and held it in 1 quarter. The position peaked at $223K in Q1 2022. 116 funds tracked by Wall St. Rank hold SANA as of Q2 2022.

Bailard reported no remaining Sana Biotechnology position as of Q2 2022 after selling out during the quarter.
Bailard sold 27,000 Sana Biotechnology shares in Q2 2022, an estimated $223K.
Bailard first reported a position in Sana Biotechnology in Q1 2022 and held it in 1 quarter.
Bailard's Sana Biotechnology position peaked at $223K in Q1 2022.
116 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.